The complement system is a highly complex and carefully regulated proteolytic cascade activated through three different pathways depending on the activator recognized. The structural knowledge regarding the intricate proteolytic enzymes that activate and control complement has increased dramatically over the last decade. This development has been pivotal for understanding how mutations within complement proteins might contribute to pathogenesis and has spurred new strategies for development of complement Schatz-Jakobsen et al -Structural aspects of complement activation and regulation 2 therapeutics. Here we describe and discuss the complement system from a structural perspective and integrate the most recent findings obtained by crystallography, small angle X-ray scattering and electron microscopy. In particular, we focus on the proteolytic enzymes governing activation and their products carrying the biological effector functions. Additionally we present the structural basis for some of the best known complement inhibitors. The large number of accumulated molecular structures enables us to visualize the relative size, position, and overall orientation of many of the most interesting complement proteins and assembled complexes on activator surfaces and in membranes.
Introduction
The complement system is an important effector of innate immunity and plays a crucial role in the detection, phagocytosis and killing of invading pathogens and clearance of immune complexes.
Complement is also increasingly recognized for its role in maintenance of host homeostasis through clearance of apoptotic and necrotic cells. Furthermore, increasing evidence supports the hypothesis of complement as a key player during the process of development (1) . Activation of the complement system relies on pattern recognition molecules (PRMs) recognizing pathogen-associated molecular patterns (PAMPs) or danger-associated molecular patterns (DAMPs) on the activator. There are three well characterized activation pathways for complement, the classical pathway (CP), lectin pathway (LP) and the alternative pathway (AP). Upon activation, all three pathways converge via AP amplification into a common terminal pathway (TP) in which the final proteolysis event elicits a potent proinflammatory response and triggers the assembly of a sophisticated membrane penetrating complex capable of killing specific pathogens.
Structural biology has during the last decade, mostly through crystallographic studies, provided a rapidly expanding platform for understanding the details of the complicated proteolytic reactions occurring during activation and regulation of these pathways. Recent technical improvements in electron microscopy (EM) now makes it possible to gain structural insights into large activator bound complement complexes such as the C1 complex from the CP (2) and the membrane attack complex (MAC) formed in the TP (3, 4) . In the following we provide an overview of recent important developments in structural biology of the complement system with focus on assembly and regulation of the large and intricate proteolytic enzymes formed upon complement activation. We also describe how these enzymes recognize and cleave their substrates. Finally, recent breakthroughs within structural studies of MAC assembly and the therapeutic inhibition of the TP are discussed.
The classical and lectin pathways The lectin pathway pattern recognition molecules and MASP proteases
Initiation of the LP takes place when PRMs bind to an activator presenting carbohydrate or acetyl groups on pathogens or abnormal host tissue and cells. The five LP PRMs possess the same overall architecture and their subunits are constructed from three chains. In each chain a short N-terminal region engages in disulfide bridges with the two other chains and other subunits, a central region assembles into a trimeric collagen stem and a C-terminal region folds into a globular domain, which interact strongly non-covalently with the equivalent domain of the two other chains. A variable number of such three-chain subunits then associate to form the functional oligomer. As an example, mannan binding lectin (MBL) is organized as oligomers with 2-8 subunits, but in serum the most abundant species are tetramers and trimers (5) . The second lectin PRM CL-LK and the three ficolins (H-ficolin, L-ficolin and M-ficolin) form oligomers in the same way (6) , but whereas MBL and the ficolins contains only one type of chains, the CL-LK subunits are most likely made from two chains of CL-K1 and one CL-L1 chain (7) . The PRMs have two spatially separated functions. At one end the globular trimeric domain known as the carbohydrate recognition domain (CRD) in the lectins and the fibrinogen-like domain (FBG) in ficolins forms multivalent interaction with specific molecular patterns on the activator (8) .
The second function of the LP PRMs located in middle of the collagen stem is to bind dimers of mannanbinding lectin associated serine proteases (MASPs). These share a conserved domain structure with two subsequent proteolytic activation of the substrates PRM:MASP-2 and C4b2 (18, 19) . However, compelling biochemical evidence showing that the initial activation of the LP occurred through intermolecular proteolytic cleavage between SP domain from different MASP dimers and that binding to a glycan as such was not needed contradicted the model (5) . This instead suggested that the activator glycan trigger LP initiation by creating a local high concentration of the PRM-MASP complexes and by orientating them correctly relative to each other. We further substantiated this alternative model by studying a complex between a predominantly tetrameric MBL in complex with a non-activated zymogen MASP-1 dimer by small angle X-ray scattering (SAXS) and negative stain EM (20) . Both approaches unequivocally showed that the MASP-1 SP domains were highly accessible and separated by more than 200 Å (Fig 1B) . These results strongly supported the alternative intermolecular activation model and appear to rule out the traditional activation model with MASP activation occurring within a dimer bound to the same PRM. Importantly, we still do not know the conformational difference between fluid phase non-activated PRM-MASP and activator bound non-activated or activated PRM:MASP complexes. Furthermore, our results do not exclude that conformational changes does occur upon activator association which might alter the accessibility of the MASP SP domains and thereby promote intermolecular activation.
Function and architecture of the C1 complex
Complement activation through the classical pathway (CP) is governed solely by the C1 complex containing the PRM C1q associated with a defined heterotetramer encompassing two subunits of both C1r and C1s, in the following denoted C1r 2 s 2 . Multivalent complexes of antigens and IgG and IgM antibodies are the best known CP activators, but the list of C1q binding patterns now comprises more than 100 targets including surface bound pentraxins and Aβ oligomers occurring in patients with Alzheimer's disease (21, 22) .
Activation of CP supports the elimination of soluble immune complexes and antibody tagged pathogens but also participates in maintenance of homeostasis through clearance of apoptotic and necrotic cells (23) .
Recent studies in mouse models have indicated a major role of C1 with respect to synaptic pruning in the nervous system during development but also in connection with pathogenesis in Alzheimer's disease and frontotemporal dementia. In either case the actual C1 binding molecular pattern on the synapse to be eliminated remains to be identified (24) (25) (26) .
The CP pattern recognition molecule C1q shares its overall structure with the lectin pathway PRMs in that it is based on a central collagen stem carrying C1r 2 s 2 , a globular C-terminal domain responsible for recognition of the activator called the gC1q domain and a short N-terminal region containing disulfide bridges. C1q has a defined stoichiometry and is based on three chains C1qA, C1qB and C1qC forming one C1q subunit, and six such subunits are assembled in C1q. The N-terminal of such six stems associate tightly in a cylinder shaped structure after which they diverge into separate collagen stems. At the junction a kink is observed, probably as a consequence of an imperfect GXY triplet pattern with an additional residue in C1qA and the presence of an alanine instead of glycine in C1qC (27) . The crystal structure of gC1q revealed a compact sphere-like heterotrimer with a diameter of 50 Å in which the three subunits are tightly associated through non-covalent interactions (28) .
In the C1r 2 s 2 tetramer, the two C1rs heterodimers associate via head-to-tail C1s-C1s CUB1-EGF contacts in a manner highly resembling that observed for MASP proteases (29) . Within the heterodimer C1r and C1s have been proposed to interact via similar head-to-tail contacts between their CUB1-EGF domains (29, 30) .
The CCP1-CCP2-SP fragments of both C1r and C1s have the same architecture as found in the MASP proteases (16, 31) , and in C1s the CUB2 and the CCP1 domains are located in plane like in MAp44 but with a rather different angle between the two domains (29) . The C1r 2 s 2 tetramer uses a total of six CUB Ca 2+ sites (four in C1r and two in C1s) to associate with C1q by contacts bridging specific lysines in C1qB and C1qC
with the C1r and C1s CUB Ca 2+ sites (32, 33) .
The structure of non-activated C1
The well-defined composition of the C1 complex as compared to the PRM-MASP complexes raises the expectation that detailed structural insight is available. Unfortunately the structural knowledge regarding the intact C1 complex is currently only of low-resolution nature. Negative stain EM pictures have for many years represented state of the art with respect to the structure of non-activated C1. These were interpreted to suggest that the central part of C1r 2 s 2 was located inside the collagen stem cone of C1q while the remaining parts of C1rs were wrapped around the collagen stems (34) . This model has subsequently been refined to a model which incorporates the partial crystal structures of C1r and C1s and the CUB-collagen interactions linking the C1q collagen stems with the C1r 2 s 2 tetramer as described above.
An essential feature of the model is that the CCP1-CCP2-SP domains of both C1r and C1s are tucked inside the C1q cone between the C1r 2 s 2 CUB1-EGF domains and the gC1q domains (30, 33) . A crystal packing interaction occurring in crystals of the C1r CCP1-CCP2-SP fragment between the C1r SP domain from one molecule and the CCP1 domain from a second molecule has been suggested to reflect an interaction between the two C1r molecules in the C1r 2 s 2 tetramer (31) . It is hypothesized that activator binding induces a conformational rearrangement in C1q collagen stems that is translated into a reorganization of C1r 2 s 2 that brings the two C1r SP domains close enough to activate each other (31, 35) . Activation of C1r
and subsequent activation of C1s in the same tetramer is then proposed to be followed by exposure of the C1s SP domain in order to allow its binding and cleavage of its substrates C4 and C4b2. In a very recent model it is suggested that activated C1s remains within the C1q cone and cleaves its substrates in this location (29) . Compared to the new and rather simple activation model for PRM:MASP complexes, the existing C1 activation models appear rather elaborate. Further validation by experimental data and in particular more detailed structural studies are needed to confirm the existing model or develop a new CP activation model.
The structure of an activator bound C1 complex
With respect to activator bound C1 a recent ground-breaking study conducted with cryo EM tomography has provided the first true structural insight into how PRM-protease complexes are bound to an activator.
In this study a liposome was decorated with dinitrophenyl hapten and a hapten-specific IgG antibody containing mutations strongly enhancing the formation of Fc hexamers (2) . Subsequently C1 was added and due to the hexameric Fc platform, which provide strong avidity to the C1-Fc interaction, well defined complexes between C1 and the hexameric Fc platform could be visualized (Fig. 1D) . The resulting tomogram confirmed the presence of a cylindrical C1 stalk containing the N-terminal part of the six collagen stems in a parallel arrangement and a central horizontal layer presumably containing C1r 2 s 2 .
However, the CCP1-CCP2-SP parts of either protease were not visible but suggested to protrude out from the center of the molecule to an exposed location (2) similar to the organization of the MBL:MASP-1 complex observed by SAXS and EM. In line with that, the C1 tomogram indeed compare very well with our SAXS based MBL:MASP-1 structure (Fig 1B and 1D) . The Fc hexamer plane was readily recognizable and parallel to the central C1r 2 s 2 layer in C1 and contacts between the Fc hexamer and four of the six gC1q domains were observed (2) . It should be noticed that the tomography study described the activator bound C1 with a relatively low resolution of 6 nm which might explain why the catalytic domains or C1r 2 s 2 and single collagen stems were not visible, but flexibility of especially the C1r and C1s EGF-CUB2 and CUB2-CCP1 junctions may also contribute.
C4 and its complex with MASP-2
Whereas an impressive number of crystal structures involving C3 and C3b have been determined since 2005, it was only in 2012 we presented the first structure of C4. One reason is perhaps that C4 is the most heterogeneous protein of the complement system. In addition to the two isotypes of the C4 gene, C4A and C4B, a total of 23 allotypes of the genes have been reported. The two isotypes differ within a short sequence of six residues that determines whether the thioester in nascent C4b preferentially reacts with amino (C4A) or alcohol (C4B) containing nucleophiles from the activator (36) . Most individuals express both isoforms and very recently the relative expression of the C4A isoform have been linked to the risk of developing schizophrenia (37) . Our structural studies on the various functional states of the human protein have all been based on C4 purified from outdated plasma likely to contain a mixture of the C4A and C4B
isotypes. The structure of C4 follows the principles first established for C3 (Fig 1E) . Eight MG domains forms the basic building blocks, six of these (MG1-MG6) are located in a helical arrangement often referred to as the MG ring. The thioester (TE) domain, the CUB domain and the MG8 domain form a tightly packed structural entity called the -chain superdomain with the thioester buried between the TE and MG8
domains. The MG7 and the C-terminal C345c domains are quite solvent exposed domains located next to and on top of the -chain superdomain, respectively. The C4a domain released upon C4 cleavage acts like a wedge between the -chain superdomain and the MG-ring (38) . Our structure of C4 in complex with a MASP-2 fragment encompassing the two CCP and the SP domains revealed an unexpected binding mode for the protease. The enzyme and the substrate interact through two major interfaces. First, the C4 scissile bond region is inserted in the catalytic site and in particular the P1 residue Arg756 is accommodated in the MASP-2 S1 pocket confirming that our structure represents a Michaelis complex. Prior biochemical experiments provided evidence for an important role of the CCP domains in both C1s and MASP-2 for C4
cleavage, and our structure confirms this by revealing a second major point of intermolecular interaction formed by the insertion of the C4 C345c domain into a cleft between the two MASP-2 CCP domains. We showed that mutation of MASP-2 residues from this interface led to strongly decreased C4 deposition, and the isolated C4 C345c domain was functional as a competitive inhibitor of C4 cleavage by C1s pointing to the relevance of this interaction for the CP as well (38) . A third minor interaction involves the C4 specific sulfotyrosine region, which appeared to be trapped by electrostatic interactions with the MASP-2 SP domain and the C4a domain. This interaction was later found to occur between the C4 sulfotyrosine region and the C1s SP domain as well (39) further supporting that C4 is recognized in the same manner by MASP-2 and C1s. The substrate C4 undergoes a significant conformational change as a result of binding MASP-2 which significantly reorders the C4a domain and the scissile bond region due to tighter contacts with the neighboring MG3 domain and the presence of the MASP-2 SP domain (38) .
Structural basis for C4b function
Our structure of the C4b product revealed a conformation that very closely resembled that of C3b (40) in agreement with their common function as the non-catalytic subunit of the convertases (see below) and their shared mechanism of regulation by FI degradation. The thioester in C4b is fully exposed and has moved by 80 Å as compared to its location in C4 due to a major rearrangement involving the TE, CUB and MG8 domains (Fig 1G) . In the crystal structure of C4b the TE domain is associated with the MG1 domain, but our SAXS studies indicated that in solution the TE domain may be separated from the MG1 domain, a phenomenon also inferred from SAXS studies of C3b (40) . Very recently, we have also determined the solution structures of the CP proconvertase C4b2 and the CP C3 convertase C4b2a (Fig 1H-I ). In crystal structures involving FB from the AP two conformations -open and closed -are known, differing by a rotation of FB SP domain, see further below for a detailed description of these. Within the CP C4b2 we clearly observed a closed conformation of C2 (41) . Our SAXS studies of CP C3 convertase was challenging due to the rapid dissociation of C2a from C4b, but by introducing stabilizing mutations in C2 and by conducting a rapid analysis using in-line SAXS that separates intact C4b2a from its dissociation products we were able to conduct the first solution study of a convertase. The resulting C4b2a conformation resembled that known from the AP C3 convertase trapped by a bacterial protein called SCIN (see below) and the C4b2a apparently does not need to undergo major conformational changes to bind and cleave its substrate C3 (41).
The alternative pathway Initiation and amplification
With the first C3b molecule formed by the CP C3 convertase, the AP takes over and strongly amplifies the initial pattern recognition events in the CP and LP. It has been estimated that up to 90% of the deposited C3b molecules are generated through the AP regardless of whether CP or LP generated C3b initiate the AP (42, 43) . The AP may however initiate without prior activation of the two other pathways. Spontaneous hydrolysis of the thioester bond in C3 -also known as tick-over -is believed to cause similar conformational change as those occurring in nascent C3b. The product C3(H 2 O) cannot covalently associate with the activator, but may be recruited to a properdin binding surface (see below). Upon association with C3(H 2 O), FB can be cleaved by FD and the resulting C3(H 2 O)Bb complex is a proteolytically active fluid-phase C3 convertase (44) . This may cleave C3 into C3a and C3b, of which some of the C3b molecules will attach covalently to hydroxyl or amino groups on surface carbohydrates and proteins in close proximity. C3b generated in by this AP initiation pathway is no different from C3b produced by the CP C3 convertase. The AP C3 convertases C3(H 2 O)Bb and C3bBb are inherently labile and dissociate irreversibly with half-lives in the range of two minutes at 37 °C (45). However, both complexes can be stabilized up to 10 fold upon binding of properdin (44, 46) . In vivo, the short convertase life-time probably represents a safety mechanism that prohibits long-term complement activation and consequently excessive generation of the strong pro-inflammatory signal molecules C3a and C5a.
Structures of the AP C3 convertase
Considerable structural information has been generated concerning the AP proconvertase. In particular, a combination of EM and crystal structures of C3bB, C3bBD, and of FB in complex with the C3b homolog cobra-venom factor (CVF) have provided valuable insight into the assembly and activation of the AP pro- binding to C4b (41) . Furthermore, the scissile bond is likely to be accessible in both C2 and C4b2 as these are cleaved with quite comparable kinetics by MASP-2, and C1s also readily turns over both substrates (53) .
Upon FD cleavage the active convertase C3bBb irreversibly dissociates within minutes making structure determination of the AP C3-convertase and its substrate complex very challenging. As a response to the function of complement to clear invading pathogens, numerous of these have evolved mechanisms to evade especially the AP and the TP in order to spread to the tissue of interest (54, 55) . Perhaps the most prominent example of how structural studies can benefit from these evasion proteins is the structure of the C3bBb complex determined using the staphylococcal complement inhibitor (SCIN). This 10 kDa protein exhibits a triple α-helical bundle structure and traps the convertase through dimerization in a very stable Chlamydia pneumoniae (61, 62) and host epithelial cells, apoptotic and necrotic T-cells, and activated platelets (63, 64) . In solid phase assays FP has been observed to bind lipooligosaccharide, lipopolysaccharide, myeoloperoxidase, and neutrophil extracellular traps (65) (66) (67) (68) (69) (70) . To what extent these observations are artifacts of high-order oligomers and aggregates of properdin is still up for discussion (71) .
FP oligomerizes and is primarily found as dimers, trimers and tetramers in plasma at a concentration of approximately 5-25 µg/ml (59, 72) . However, even higher oligomers may be formed during purification and storage, and the properties of FP depend on its oligomeric state, complicating performance of functional studies of the protein (71) . No high-resolution structure of FP is available but based on sequence homology it is predicted to contain seven thrombospondin repeats (TSRs). Studies involving recombinant FP showed that variants lacking TSR6 are unable to form oligomers and that both TSR4 and TSR5 are important for binding to C3b and stabilization of C3bBb, whereas TSR3 is dispensable (73) . Based on EM and SAXS studies, FP is thought to oligomerize in a head-to-tail fashion (74, 75) . A recent EM study clearly showed that FP contains one vertex per monomer, which was suggested to contain four TSR domains from two separate monomers leaving three domains to form the elongated connections between vertexes (75). This study also suggested a structure of the FP-stabilized AP C3 convertase C3bBbP. The vertices of triangular or square FP trimers/tetramers were found to contact the C3b C345c domain and the Bb vWA domain offering an explanation for its stabilizing effect on the AP C3 convertase (75) . In Figure 3D we present the FP vertex envelope from the EM study in the correct scale on top of the SCIN stabilized AP convertase C3bBb.
Decay acceleration and FI cofactors
Healthy host cells may become tagged by C3b due to the generation of C3(H 2 O) in the AP or through the "bystander" effect whereby C3b generated from any of the three pathways in the vicinity becomes domains, but the orientation of CCP4 relative to CCP3 is different for C3b bound SPICE and MCP although the overall L-shape is preserved (85) . FH contacts the C3b Nt-α' region, the MG domains 1, 2, 6, 7, and the TE domain ( Fig 2E) and this overall binding scheme is also observed for the other four regulators and will most likely also apply to regulators binding C4b as well (85) . A comparison with the structure of C3bBb ( Fig   2D) complexes readily reveals that Bb and the first two CCP domains of FH competes for C3b thus offering an explanation for the decay accelerating activity exerted by FH CCP1-4 and equivalent CCP domains in the other cofactors. In the structure of the C3b-MCP complex the equivalent of these CCP domains are not stably bound to C3b but instead mobile, which provides a rationale for its lack of decay acceleration activity (85) . FH CCP domains 2-3 and their equivalent CCP domain in the other regulators bind next to the CUB domain and may together with the C3b C345c domain provide the binding platform for FI allowing it to cleave twice in the CUB domain (78) . The crystal structure of FI (Fig 2E) revealed a zymogen like conformation of its SP domain although it had undergone maturation. Presumably a ternary complex between C3b, the cofactor and FI has to be formed to induce the catalytically competent state of FI (78) .
The terminal pathway C5 cleavage and biological effector function of cleavage products
The terminal pathway is initiated once a certain density of C3b has been reached on the activator as this trigger a shift in substrate specificity for the C3 convertases, which will make them cleave C5 instead of C3 (Fig. 3A) . Cleavage of the C5 scissile bond (R751-L752) results in formation of the effector molecules C5a
and C5b. The anaphylatoxin C5a will through binding to C5aR1 and C5aR2 on host cells induce a number of inflammatory events including phagocytosis, leukocyte recruitment, stimulation of oxidative burst, histamine release, and vasodilation (reviewed in (86)). C5 does not feature the internal thioester making the C5b molecule incapable of binding covalently to the activator surface, instead nascent C5b captures C6.
To the resulting C5b6 complex, C7, the C8 αβγ complex and 12-18 copies of C9 adds sequentially during the assembly of the membrane attack complex (MAC), also referred to as the C5b-9 complex (55). The complexes formed from C5b6 and onwards are also collectively referred to as terminal complement complexes (TCC). Parts of C6-C9 will refold into transmembrane β-hairpins (TMHs) that will insert into the lipidic bilayer of a membrane near the activator. This resulting insertion of MAC into pathogenic cell membranes or dysregulated host cell membranes may lyse the targeted cell (55).
C5 recognition by convertases
Although C3 convertases can cleave C5, it has long been known that the the formation of an efficient C5 convertase requires a certain density of C3b on the activator (87) . To facilitate the following discussion we define C3b' as one or more C3b molecules that confer high affinity for C5 to the CP C4b2a or the AP C3bBb convertases. It is important to distinguish C3b' from the Bb-bearing C3b in the AP C3 convertase. We can now define the C5 convertases as C4b2a3b' or C3bBb3b', but the exact relationship between the C3b' and the two other subunits is controversial (see below). Kinetic studies found that the C5 convertases bind the substrate with a K M of 5-180 nM depending on the surface/activator and the method employed to obtain high C3b density (88, 89) . These affinities are well below the physiological concentration of C5 (0.4 µM)
suggesting that C5 convertases readily bind their substrate (89) . However, the turnover number for cleavage is 1.44 and 0.33 C5 molecules min -1 for the CP and AP C5 convertase, respectively, making the C5 cleavage one of the slowest reactions experimentally investigated. Interestingly, whereas the presence of C3b' strongly improves the affinity for C5 as compared to the corresponding C3 convertase, the turn over number is more or less unchanged (89) .
Due to the inherent instability of the C5 convertases and difficulty in fluid phase reconstitution, there is no detailed structural knowledge regarding these pivotal proteases. In order to clarify how convertases recognise their substrates we took advantage of CVF from Naja naja. CVF lacks the TE domain but 
Assembly of the MAC
Nascent C5b undergoes a major conformational change, but in contrast to the TE domain in C3b and C4b, the C5d domain of C5b only travels halfway down from MG-ring due to its association with C6, that extensively interacts with this C5b domain as well as the MG1, MG2, MG4, C5d and CUB domains (Fig. 3D ) (95, 96) . A comparison with the structure of unbound C6 reveals that the C-terminal CCP and factor I-MAC (FIMAC) domains rotate and translate by 158° and 115 Å, respectively, relative to the central MAC-perforin (MACPF) domain upon binding to C5b (97) . It has been suggested that the C5b6 complex is able to stay associated with the C5 convertases (98, 99) , and a structural alignment of the C5:CVF and C5b6 complexes suggests that most of the MG4-MG5 domain interface is retained and accessible in C5b whereas the orientation of the MG7 domain is altered. The putative contact between C5b6 and the activator bound C5
convertase may help to orient the C6 molecule correctly towards the extracellular membrane leaflet (Fig.   3D ). The C5b6 complex functions as a receptor for C7 that confers lipophilicity to the resulting C5b-7 complex (100). Subsequently the C8αβγ complex will associate with the C5b-7 complex through a C7:C8β interaction (101) . The TMHs of C8α, C8β and C9 facilitate the membrane penetration and induce the pore formation through C9 polymerisation. Recently published cryo-EM and cryo-ET structures of the entire MAC (Fig. 3E) , either solubilized in detergents or formed on liposomes, respectively, describes a heterogeneous pore with a split-washer conformation (3, 4) . The transmembrane region of the MAC does not form an idealized β-barrel as it might have been expected. The inner and outer diameters of the pore are around 11 and 25 nm, respectively, but the pore is not completely closed on the face where the initiating C6 molecule faces the terminating C9 molecule. The terminating C9 is located closer to the center compared to C6 and the initiating and terminating ends of the pore are twisted somewhat upwards and downwards, respectively, as compared to the rest of the MAC pore. In the cryo-EM structure, the MAC consists of C5b-8 and 18 C9 molecules, whereas only 16 C9 molecules were placed in the cryo-ET structure (3, 4) . From the cryo-ET studies it was moreover found that whereas half of the pores identified were single C5b-9 ring structures, the other half were multimeric pores formed from C5b-8 complexes associating with each other (4).
Structure and therapeutic inhibition of C5a
Due to the high potency of C5a with respect to induce pro-inflammatory signaling, the activity of C5a is tightly regulated by carboxypeptidase cleavage of the C-terminal Arg751 resulting in C5a-desArg that retains up to 50% of its efficiency as compared to full-length C5a depending on the system used to evaluate activity (102) (103) (104) . Both as a domain within C5 and as isolated protein C5a is comprised of four antiparallel helices stabilised by three disulphide bridges connecting helices 2, 3 and 4. In most structures helix 1 interacts with helices 2 and 4 (105-107) -a pattern also found in C3a (108, 109) . However, structures of human C5a-desArg and an antagonistic version of C5a (A8C5a) revealed two conformations in which helix 1 was released from the disulphide bridged core encompassing helices 2-4 (103, 110). The flexible nature of helix 1 might be of importance in C5 biology. All known structures of C5 feature Arg751 as inaccessible. We suggested that detachment of helix 1 from its contacts with helix 2 and 4 within C5 would allow unfolding of the scissile bond region (93) . Secondly, the distance from the C-terminal residue L673 in the LNK region to the N-terminal Thr678 of C5a is 58 Å, which is too far to span with the four residues found in the pro-C5.
Hence, helix 1 may adopt the extended conformation prior to the furin processing step of pro-C5 (94). The C-terminus of free C5a is very flexible in most crystal structures, but in the NMR structure of human C5a, residues 746-751 forms an extra small helix pointing towards helix 1 (107) . Interestingly, a helical conformation of residues 746-754 is also observed in our recent crystal structure of C5 in complex with an eculizumab Fab fragment (111) and in the C5:OmCI:RaCI complex (112) .
Mutational studies suggest that C5a possess two surface patches mainly involved in C5aR1 binding and signalling, respectively. The first patch includes basic residues within the disulphide bridged three-helical core and is essential for the high affinity binding towards C5aR1. The second patch consists of the Cterminus, of which the last eight residues is the minimal motif that may activate C5aR1. We have recently presented the structure of mouse C5a bound to the inhibitor NOX-D20, an L-RNA/L-DNA aptamer developed by NOXXON Pharma AG (113) . Our structure revealed that NOX-D20 renders patch 1 of C5a inaccessible for receptor binding. This suggests that NOX-D20 works by inhibiting the high affinity binding of C5a to C5aR1 rather than directly preventing the receptor activating part of C5a in patch 2 from interacting with the receptor (Fig. 3F) .
Therapeutic inhibition of C5 by eculizumab
The insertion of MAC in membranes of non-altered self-cells is normally prevented by either MAC specific regulators or by upstream control of convertases (reviewed in (92)). In some diseases, this regulation however is abnormal. The most prominent example is paroxysmal nocturnal hemoglobinuria (PNH) which is caused by a somatic mutation in the X-linked PIGA gene resulting in deficiency of the PIG-A protein involved in the addition of a glycophosphatidylinositol (GPI) anchor to proteins (114, 115) . This modification is functionally essential as it targets the GPI carrying protein to the outer leaflet of plasma membranes. Two such proteins are DAF/CD55 and CD59. Whereas CD55 negatively regulates the AP through its dissociation of convertases, CD59 directly blocks MAC assembly. The PIG-A mutation leads to an expansion of hematopoietic stem cells with a deficiency in the pathway for addition of GPI-linkages resulting in erythrocytes lacking these regulators. Uncontrolled C3 and C5 consumption combined with an ablated MAC-inhibitory mechanism confer constant formation of TCC complexes on these erythrocytes leading to severe hemolysis (116) . Another example of a disease caused by insufficient complement regulation is atypical hemolytic uremic syndrome (aHUS), a rare and life-threatening disease involving hemolysis and dysfunctions of the kidney. AP dysregulation conferring over-activation of C3 on erythrocytes, platelets and endothelial cells results in excessive amounts of MAC formation and are characteristics of aHUS (117, 118) .
Mutations leading to loss-of-function in AP regulators such as FH or FI either alone or in combination with gain-of-function mutations in C3 or FB result in C3 convertases with an apparent enhanced stability. Also FH autoantibodies have been found to increase the risk of aHUS development (119).
The monoclonal antibody eculizumab (also known as Soliris) manufactured by Alexion Pharmaceuticals has been used to treat PNH and aHUS in the clinic for almost a decade. Eculizumab is a humanized antibody selected in mice by immunization with human C5. The antibody binds human C5 with an affinity of 120 pM and is highly species specific. Most recently we have determined the crystal structure of C5 bound to a Fab fragment with a sequence identical to eculizumab (called ecuFab) (111) . The structure reveals how all complementarity determining regions (CDRs) of ecuFab except light chain CDR2 are involved in C5
recognition. The C5 epitope is exclusively located within the MG7 domain and ecuFab binds orthogonal to the major axis of its antigen and is protruding out in a very distinct manner from the C5 molecule (Fig. 3G ).
Our crystal structure is in complete agreement with a low resolution negative stain EM envelope of C5 bound to OmCI, RaCI and ecuFab (112) . The C5-ecuFab interface we observed was validated by a complete mutational scan of all CDR residues which identified 28 residues of importance for the binding to C5.
Despite the limited resolution of 4.2 Å for the C5-ecuFab structure we were able to rationalize why these mutations altered C5 binding. We could further pinpoint C5 Trp917 as a major contributor to the epitope, which neatly explains the strict species specificity of eculizumab. Moreover we were able to suggest why PNH patients possessing C5 with the mutations Arg885His and Arg885Cys are non-responsive to eculizumab treatment (120) . The ecuFab forms a large binding pocket for Arg885 that involves numerous residues within all heavy chain CDR regions (111) . A histidine or a cysteine at the 885 position in C5 is too small to fill this pocket, and its presence will most likely destabilize the conformation of the pocket forming CDR loops.
Comparison of the CVF and ecuFab interface on the C5 MG7 domain revealed massive overlap suggesting that eculizumab works by sterically hindering C5 binding to the convertases and not by preventing access to the scissile bond region or by inducing a C5 conformation incompatible with convertase binding and subsequent cleavage (111) .
Complement evasion at the C5 level
The TP is frequently target for pathogen complement evasion strategies. Here we focus on structures of C5 (Fig. 3I) . The β-sheet of SSL7 and the interacting β-sheet from the C5 MG5 domain interact through pairing of two β-strands, resulting in an intermolecular continuous nine stranded β-sheet (126).
SSL7 binds more than 70 Å from the C5 convertase cleavage site and does not induce large conformational changes in the C5 molecule allowing C5 recognition by the convertases. This agrees with data showing that in the absence of IgA, SSL7 does not significantly inhibit C5 cleavage (126, 127) . In vivo SSL7 completely prevents C5 cleavage by simultaneously binding to the Fc-region of an IgA molecule and C5 resulting in a pentameric IgA-SSL7 2 -C5 2 complex in which convertase binding is prevented by massive steric hindrance (94, 126) .
The quaternary structure of C5 convertases
The clincal succes of eculizumab has conclusively demonstrated that inhibition of the TP and in particular C5 cleavage may cure some complement related diseases without serious adverse effects (128) . A detailed structure based understanding of the C5 convertase could strongly accelerate development of novel TP targeted therapeutics. To date it has not been possible to reconstitute a fluid phase C5 convertase containing C3b'. Early studies suggested that C3b' has to be activator bound in a specific manner whereas both the CP and the AP C3 convertase can be recruited from the fluid phase once C3b' is present (129) . A recent study with C3b immobilised on streptavidin beads through a biotinylated thioester ensuring a 'native'-like orientation of both the C3b and the C3b' on the activator appears as a promising system for controlled reconstitution and functional analysis of C5 convertases that could pave the way for detailed structural insight. It was found that an average intermolecular distance of a maximum of 140 Å between the involved C3b molecules was needed to form an efficient C5 convertase suggesting that the C3b molecules actually have to be in physical contact (130) . The C3b molecules must also be oriented specifically relative to the activator since randomly coupled C3b did not support C5 convertase activity. In the CP C5 convertase the function of C3b' is easier to analyze as it cannot be confused with the C2a-bearing C4b. Serine 1236 in human C4b is capable of exerting a nucleophilic attack on the thioester bond in nascent C3b', resulting in a well-defined and specific covalent C4b3b' dimer (131, 132) . This occurs with a remarkably high efficiency of more than 50% during self-amplification on red blood cells. The resulting
C4b3b' binds C5 with high affinity in the absence of C2a, and the high-affinity site was inhibited by both C3
and C4 antibodies (131) . The covalent C4b-C3b' linkage is however not a prerequisite for the CP C5
convertase, since C4b mutants of Ser1236 still forms a non-covalent complex with the metastable C3b' molecule resulting in an enzyme with activity comparable to the CP C5 convertases formed with wt C4b (132) . Taken together these findings suggest that a specific non-covalent complex between C4b and nascent C3b' is formed on an activator and within this complex the covalent linkage may be formed.
Similarly, it was found that two C3b molecules may be linked if a nucleophile from an activator bound C3b reacts with the thioester in a second nascent C3b. However, the identity of the C3b nucleophile, if specific, is still unknown (133, 134) .
There are at least two ways in which C3b' might contribute to the high C5 affinity. In an allosteric model, C3b' induce a conformational change in C3bBb or C4b2a leading to high C5 affinity but does not interact directly with the substrate (Fig. 3J) . This model requires well-defined C4b-C3b' and C3b-C3b' complexes and based on the crystal structure and SAXS studies of C4b and the well characterized C4b-C3b' crosslink we proposed that the C3b' molecule might associate with the CP C3 convertase such that the FH interface of C3b' is shielded by the interaction with the C4b molecule (135) . An alternative mechanism is the sandwich model in which C3b' does not form a well-defined complex with C3bBb/C4b2a but instead contributes by recruiting C5 and perhaps primes its conformation for convertase binding and subsequent cleavage. The substrate may either bind simultaneously to C3b' and the C3 convertase (Fig. 3K) or first bind to C3b' and then diffuse to a nearby C3 convertase (Fig. 3L ). The sandwich model was proposed already in the 70s (129) but the identification of especially the C4b-C3b' dimers led to the perception of a preformed C5 convertase with a defined stoichiometry in which C3b' is located in specific manner relative to the two other C3
convertase subunits (131) . The sandwich/C5 priming model has recently been revitalized based on experiments indicating that at high concentrations the ecuFab:C5 complex may compete with C5 for binding to the AP C5 convertase in apparent contradiction to our structure of the C5:ecuFab complex (112).
The competition effect could therefore mirror C5 interaction with C3b' rather than with C3bBb. Alternative explanations could be that ecuFab:C5 may be able to form weak contacts with a preassembled C5
convertase through the MG4-MG5 interface known from the C5:CVF complex or that C5 cleavage is so slow (see above) that ecuFab can displace convertase bound C5 before the actual cleavage takes place. Further experiments with both CP and AP C5 convertases and in particular C3b binding inhibitors with a known binding site like compstatin, CRIg and the S77 Fab might be informative. Perhaps a structure of the C5 convertase with bound C5 on an activator model obtained with EM-tomography -as pioneered with the C1 complex and the MAC (2, 4) -will be needed to decide between the two models.
Conclusions and outlook
Future increasingly reliable models for the large scale geometry and architecture of complement will form the basis for improving our mechanistic understanding of complement activation, convertase assembly and the regulation. We predict that this will significantly accelerate the generation of new complement therapeutics as exemplified by the development of mini-FH, a fusion protein with a linker connecting FH CCP1-4 and CCP19-20 (136) . The recent technical improvements in EM and the successful demonstration that application of cryo-EM and cryo-ET can be used to structurally describe large complexes of the complement system (2-4) and pave the way for more structures of activator and membrane associated complement molecules in the coming years. This will hopefully result in higher resolution structures of the activating complexes giving a more detailed insight into the physiological relevance of intra-vs intermolecular activation of C1 and PRM:MASP complexes. Additionally, structures of activating complexes with C4 and C4b2 bound could further elaborate on the assembly and orientation of CP C3 convertase on the activator surface. And although we start to appreciate how FP stabilizes the AP convertases, a much more detailed understanding is needed to truly understand how this important AP regulator functions.
Another pending question is the functional composition of the C5 convertases, and also in this regard the use of properdin for stabilization might be beneficial in reconstituting the AP C5 convertase. Finally, the commercial interest in understanding anaphylatoxin signaling and activation due to the steadily accumulating data linking uncontrolled C3aR/C5aR signaling to the development of several disorders (137) combined with the expanding field of crystallography based GPCR structural biology (138) might result in structures of C3aR/C5aRs bound to agonists and antagonists. Such structures will form neat platforms for structure based engineering to improve therapeutics targeting anaphylatoxin receptors in terms of affinity and selectivity. 
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